Advaxis (ADXS)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	4.88 mm	4.88 mm	4.88 mm	4.88 mm	4.88 mm	4.88 mm
Cash burn (monthly)	3.08 mm	1.69 mm	8.19 mm	4.36 mm	2.40 mm	2.46 mm
Cash used (since last report)	43.37 mm	23.85 mm	115.31 mm	61.35 mm	33.80 mm	34.60 mm
Cash remaining	-38.49 mm	-18.97 mm	-110.43 mm	-56.46 mm	-28.92 mm	-29.71 mm
Runway (months of cash)	-12.5	-11.2	-13.5	-13.0	-12.0	-12.1

Beta Read what these cash burn values mean

Financial data from Advaxis earnings reports.

Institutional ownership, Q2 2024

ADXS institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	6	5	+20.0%
Opened positions	1	0	NEW
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	54.96 mm	54.96 mm	–
Total shares	60.94 mm	60.94 mm	–
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Israel Biotech Fund I	50.74 mm	$42.62 mm	0.0%
Lincoln Park Capital Fund	4.59 mm	$2.63 mm	0.0%
AMGN Amgen	3.05 mm	$8.49 mm	0.0%
CVI Investments	2.00 mm	$697.00 k	0.0%
Yair Chaim Schindel	560.60 k	$523.00 k	0.0%
Proequities	0.00	$0.00

Largest transactions	Shares	Change
AMGN Amgen	3.05 mm	0.0%
Proequities	0.00
Lincoln Park Capital Fund	4.59 mm	0.0%
CVI Investments	2.00 mm	0.0%
Israel Biotech Fund I	50.74 mm	0.0%
Yair Chaim Schindel	560.60 k	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ADXS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Mar 24	Israel Biotech Fund I	Warrants Common Stock	Option exercise	Acquire M	Yes	No	0.4	2,250,000	900.00 k	13,462,500
1 Mar 24	Israel Biotech Fund I	Warrants Common Stock	Option exercise	Acquire M	Yes	No	0.4	2,250,000	900.00 k	7,837,500
1 Mar 24	Israel Biotech Fund I	Convertible Promissory Note Common Stock	Option exercise	Acquire M	Yes	No	0.4	1,500,000	600.00 k	11,212,500
1 Mar 24	Israel Biotech Fund I	Convertible Promissory Note Common Stock	Option exercise	Acquire M	Yes	No	0.4	1,500,000	600.00 k	5,587,500
1 Mar 24	Israel Biotech Fund I	Rights Common Stock	Option exercise	Dispose M	Yes	No	0.4	3,750,000	1.50 mm	9,712,500
1 Mar 24	Israel Biotech Fund I	Rights Common Stock	Option exercise	Dispose M	Yes	No	0.4	3,750,000	1.50 mm	4,087,500
7 Feb 24	Israel Biotech Fund I	Common Stock, par value $0.001 per share	Payment of exercise	Dispose F	Yes	No	1.2465	2,586,905	3.22 mm	25,130,903
7 Feb 24	Israel Biotech Fund I	Common Stock, par value $0.001 per share	Option exercise	Acquire M	Yes	No	0.4	8,062,500	3.23 mm	27,717,808
7 Feb 24	Israel Biotech Fund I	Common Stock, par value $0.001 per share	Payment of exercise	Dispose F	Yes	No	1.2465	2,707,581	3.37 mm	20,661,639
7 Feb 24	Israel Biotech Fund I	Common Stock, par value $0.001 per share	Option exercise	Acquire M	Yes	No	0.4	8,437,500	3.38 mm	23,369,220

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

29 Jan 25

Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related